DE69719755T2 - Polymorphe verbindungen - Google Patents
Polymorphe verbindungenInfo
- Publication number
- DE69719755T2 DE69719755T2 DE69719755T DE69719755T DE69719755T2 DE 69719755 T2 DE69719755 T2 DE 69719755T2 DE 69719755 T DE69719755 T DE 69719755T DE 69719755 T DE69719755 T DE 69719755T DE 69719755 T2 DE69719755 T2 DE 69719755T2
- Authority
- DE
- Germany
- Prior art keywords
- fluvastatin sodium
- sodium
- fluvastatin
- water
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims abstract description 166
- 229960000868 fluvastatin sodium Drugs 0.000 claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 34
- 229960003765 fluvastatin Drugs 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 239000002904 solvent Substances 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 33
- 238000002425 crystallisation Methods 0.000 claims description 25
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 230000008025 crystallization Effects 0.000 claims description 24
- 239000003960 organic solvent Substances 0.000 claims description 23
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 21
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 18
- 238000001556 precipitation Methods 0.000 claims description 14
- 230000001376 precipitating effect Effects 0.000 claims description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 8
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- -1 if necessary Substances 0.000 claims description 4
- 238000002329 infrared spectrum Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000000879 anti-atherosclerotic effect Effects 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 150000003388 sodium compounds Chemical class 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 239000003495 polar organic solvent Substances 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 3
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 238000010899 nucleation Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 30
- 239000013078 crystal Substances 0.000 description 22
- 239000002002 slurry Substances 0.000 description 15
- 239000010410 layer Substances 0.000 description 14
- 239000000047 product Substances 0.000 description 14
- 238000002156 mixing Methods 0.000 description 10
- 150000004682 monohydrates Chemical class 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 238000001953 recrystallisation Methods 0.000 description 5
- 239000011877 solvent mixture Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000002336 sorption--desorption measurement Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 238000009736 wetting Methods 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 230000001125 hyperlipoproteinemic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010034960 Photophobia Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 206010057040 Temperature intolerance Diseases 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000011229 interlayer Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 208000013469 light sensitivity Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000012762 regulation of cholesterol biosynthetic process Effects 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000012780 transparent material Substances 0.000 description 1
- 229910052724 xenon Inorganic materials 0.000 description 1
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Indole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9602477A SE9602477D0 (sv) | 1996-06-24 | 1996-06-24 | Polymorphic compounds |
| SE9700751A SE9700751D0 (sv) | 1997-03-03 | 1997-03-03 | Polymorphic compounds |
| PCT/SE1997/001097 WO1997049681A1 (en) | 1996-06-24 | 1997-06-18 | Polymorphic compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69719755D1 DE69719755D1 (de) | 2003-04-17 |
| DE69719755T2 true DE69719755T2 (de) | 2003-11-20 |
Family
ID=26662685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69719755T Expired - Lifetime DE69719755T2 (de) | 1996-06-24 | 1997-06-18 | Polymorphe verbindungen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6124340A (enExample) |
| EP (1) | EP0907639B1 (enExample) |
| JP (2) | JP4282092B2 (enExample) |
| AT (1) | ATE234282T1 (enExample) |
| AU (1) | AU3366297A (enExample) |
| CY (1) | CY2461B1 (enExample) |
| DE (1) | DE69719755T2 (enExample) |
| DK (1) | DK0907639T3 (enExample) |
| ES (1) | ES2194202T3 (enExample) |
| PT (1) | PT907639E (enExample) |
| WO (1) | WO1997049681A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9902202D0 (sv) | 1999-06-10 | 1999-06-10 | Astra Ab | Production of aggregates |
| US6242003B1 (en) | 2000-04-13 | 2001-06-05 | Novartis Ag | Organic compounds |
| AU2002223639B2 (en) | 2000-10-31 | 2006-06-22 | Ciba Specialty Chemicals Holding Inc. | Crystalline forms of fluvastatin sodium |
| US20060127474A1 (en) | 2001-04-11 | 2006-06-15 | Oskar Kalb | Pharmaceutical compositions comprising fluvastatin |
| ES2304140T3 (es) * | 2001-08-03 | 2008-09-16 | Ciba Holding Inc. | Formas cristalinas de sodio de fluvastatina. |
| GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| DE10316087A1 (de) * | 2003-04-08 | 2004-11-11 | Ratiopharm Gmbh | Polymorphstabilisierung von Fluvastatin-Natrium in Pharmazeutischen Formulierungen |
| WO2004096765A2 (en) * | 2003-05-01 | 2004-11-11 | Morepen Laboratories Ltd. | A novel crystalline polymorph of fluvastatin sodium and a process for preparing it |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| CA2529859A1 (en) * | 2003-06-18 | 2004-12-29 | Teva Pharmaceutical Industries Ltd | Fluvastatin sodium crystal forms xiv, lxxiii ,lxxix, lxxx and lxxxvii, processes for preparing them, compositions containing them and methods of using them |
| US7368468B2 (en) * | 2003-06-18 | 2008-05-06 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them |
| US7368581B2 (en) * | 2003-06-18 | 2008-05-06 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of fluvastatin sodium crystal from XIV |
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| WO2005037787A1 (en) * | 2003-10-16 | 2005-04-28 | Ciba Specialty Chemicals Holding Inc. | Crystalline form of fluvastatin sodium |
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| US7851624B2 (en) * | 2003-12-24 | 2010-12-14 | Teva Pharamaceutical Industries Ltd. | Triol form of rosuvastatin and synthesis of rosuvastatin |
| US20070179166A1 (en) * | 2003-12-24 | 2007-08-02 | Valerie Niddam-Hildesheim | Process for preparation of statins with high syn to anti ratio |
| US7241800B2 (en) | 2004-03-17 | 2007-07-10 | Mai De Ltd. | Anhydrous amorphous form of fluvastatin sodium |
| US20080269188A1 (en) * | 2004-07-21 | 2008-10-30 | Inserm | Oatp-C Gene C463a Polymorphism Underlies Variable Response to Statin Therapy |
| US7371906B2 (en) * | 2004-08-24 | 2008-05-13 | Eastman Kodak Company | Process for photo-oxidative stability improvements |
| WO2006021967A1 (en) * | 2004-08-26 | 2006-03-02 | Biocon Limited | Process for the preparation of fluvastatin sodium form a. |
| WO2006030304A2 (en) * | 2004-09-17 | 2006-03-23 | Ranbaxy Laboratories Limited | Novel forms of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof |
| CA2583312A1 (en) * | 2004-10-05 | 2006-04-13 | Biocon Limited | Process for the preparation of amorphous fluvastatin sodium |
| WO2006085338A2 (en) * | 2005-02-11 | 2006-08-17 | Jubilant Organosys Limited | Novel polymorphic forms of fluvastatin sodium and process for preparing the same |
| WO2006109147A1 (en) * | 2005-04-12 | 2006-10-19 | Glenmark Pharmaceuticals Limited | Substantially pure amorphous fluvastatin, processes for its preparation and pharmaceutical compositions containing same |
| WO2007100894A2 (en) * | 2006-02-27 | 2007-09-07 | Teva Pharmaceutical Industries Ltd. | Fluvastatin sodium novel forms and preparation therof |
| ATE431818T1 (de) | 2006-04-20 | 2009-06-15 | Italiana Sint Spa | Verfahren zur herstellung von fluvastatin-natrium |
| CN101250153B (zh) * | 2008-02-26 | 2013-09-18 | 深圳信立泰药业股份有限公司 | 一种制备氟伐他汀钠晶型的工艺 |
| WO2010118757A1 (en) * | 2009-04-15 | 2010-10-21 | Pharmathen S.A. | Improved process for the preparation of fluvastatin and salts thereof |
| CN114280181B (zh) * | 2021-12-23 | 2024-06-18 | 浙江海翔川南药业有限公司 | 一种瑞舒伐他汀中间体及其有关物质的检测方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984002131A1 (fr) * | 1982-11-22 | 1984-06-07 | Sandoz Ag | Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| HU9203780D0 (en) * | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
-
1997
- 1997-06-18 AU AU33662/97A patent/AU3366297A/en not_active Abandoned
- 1997-06-18 AT AT97929654T patent/ATE234282T1/de active
- 1997-06-18 DK DK97929654T patent/DK0907639T3/da active
- 1997-06-18 WO PCT/SE1997/001097 patent/WO1997049681A1/en not_active Ceased
- 1997-06-18 ES ES97929654T patent/ES2194202T3/es not_active Expired - Lifetime
- 1997-06-18 PT PT97929654T patent/PT907639E/pt unknown
- 1997-06-18 EP EP97929654A patent/EP0907639B1/en not_active Expired - Lifetime
- 1997-06-18 JP JP50282198A patent/JP4282092B2/ja not_active Expired - Lifetime
- 1997-06-18 US US08/875,203 patent/US6124340A/en not_active Expired - Lifetime
- 1997-06-18 DE DE69719755T patent/DE69719755T2/de not_active Expired - Lifetime
-
2004
- 2004-06-17 CY CY0400049A patent/CY2461B1/xx unknown
-
2009
- 2009-01-09 JP JP2009003704A patent/JP2009149654A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US6124340A (en) | 2000-09-26 |
| PT907639E (pt) | 2003-06-30 |
| EP0907639B1 (en) | 2003-03-12 |
| WO1997049681A1 (en) | 1997-12-31 |
| JP2000512992A (ja) | 2000-10-03 |
| ATE234282T1 (de) | 2003-03-15 |
| DE69719755D1 (de) | 2003-04-17 |
| JP2009149654A (ja) | 2009-07-09 |
| CY2461B1 (en) | 2005-06-03 |
| JP4282092B2 (ja) | 2009-06-17 |
| AU3366297A (en) | 1998-01-14 |
| ES2194202T3 (es) | 2003-11-16 |
| DK0907639T3 (da) | 2003-06-23 |
| EP0907639A1 (en) | 1999-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69719755T2 (de) | Polymorphe verbindungen | |
| US5488150A (en) | Crystals of N-(trans-4-isopropylcyclohexycarbonyl)-D-phenylalanine and methods for preparing them | |
| DE3881249T2 (de) | Fettsaeureamide als acyl-coa-inhibitoren: cholesterolacyltransferase. | |
| DE29724281U1 (de) | 4-Phenylpiperidin-Verbindungen | |
| WO2005028468A1 (de) | 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel | |
| DE19546249A1 (de) | Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen | |
| DE19918588A1 (de) | Piperidinverbindung | |
| DE202007019460U1 (de) | Kristalline Tigecyclin-Formen | |
| DE112012004944T5 (de) | Kristalline Formen von Cabazitaxel und deren Herstellungsverfahren | |
| EP0550895B1 (de) | 4,13-Dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE60131416T2 (de) | Chirale fluochinolon-argininsalzformen | |
| DE69811500T2 (de) | Kristallmodifikation von 1-(2,6-difluorbenzyl)-1h-1,2,3-triazol-4-carbonsäureamid und seine verwendung als antiepileptikum | |
| LU84657A1 (de) | Neue kristallmodifikationen,verfahren zu deren herstellung und die sie enthaltenden pharmazeutischen zusammensetzungen | |
| DE69510999T2 (de) | Terazosinmonohydrochlorid und Verfahren und Zwischenprodukte für seine Herstellung | |
| DE69917282T2 (de) | Verfahren zur herstellung von zofenopril-calciumsalz | |
| DE3443065A1 (de) | Kristallines cephalexinhydrochloridmonohydrat, verfahren zu seiner herstellung und seine verwendung | |
| DE69706562T2 (de) | N-(4-acetyl-1-piperazinyl)-4-fluorobenzamidhydrat | |
| AT403162B (de) | Neue kristallform von morphin-6-glucuronid | |
| DE3789264T2 (de) | Beta-lactam-antibiotika. | |
| DE20220885U1 (de) | Kristallines und amorphes Mupirocin-Calcium | |
| DE69600565T2 (de) | Kristaliner Polymorph von Terazosin und dies enthaltende pharmazeutische Zusammensetzungen | |
| DE2513136C3 (de) | N-(1-Benzylpiperid-4-yl)-benzamide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| DE69718216T2 (de) | Polymorphe von donepezyl-hydrochlorid und verfahren zur herstellung | |
| EP0849265A1 (de) | Neue polymorphe Form von Doxazosin-Mesylat (Form II) | |
| CN110804080B (zh) | 乙酰氨基阿维菌素晶型a、晶型b、非晶体及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| 8328 | Change in the person/name/address of the agent |
Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN |